Mode
Text Size
Log in / Sign up

CFH Y402H and ARMS2 A69S polymorphisms are associated with increased risk of age-related macular degenerationSpecific genes linked to higher risk of age related macular degeneration

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that CFH Y402H and ARMS2 A69S polymorphisms are significantly associated with increased risk of age-related macular degeneration.

This meta-analysis investigates the association between specific genetic polymorphisms, specifically CFH (Y402H, rs1061170) and ARMS2 (A69S, rs10490924), and the risk of age-related macular degeneration (AMD). The study also synthesized data regarding the prevalence of high-risk genotypes among patients and potential responses to anti-VEGF treatment.

The meta-analysis identified a significant association between the CFH Y402H polymorphism and increased AMD risk (OR 2.25; 95% CI: 1.27-4.00, p=0.006). Additionally, a strong genetic association was found for ARMS2 polymorphisms (OR 4.05; 95% CI: 1.79-9.16, p<0.001). However, the prevalence of high-risk genotypes among AMD patients did not reach statistical significance (OR 1.439; 95% CI: 0.929-2.231, p=0.103) due to substantial heterogeneity.

The authors note that while these genetic markers are associated with risk, potential gene-environment interactions may exist. The findings suggest a possible role for genetic screening in AMD risk assessment and the development of personalized treatment strategies. Clinical application is currently limited by the observed heterogeneity across studies.

How this fits prior evidence

This meta-analysis extends previous evidence regarding age-related macular degeneration (AMD) by identifying specific genetic markers associated with increased disease risk. While prior coverage established that age, smoking, and systemic factors are associated with increased AMD risk, this study focuses on the role of CFH Y402H (OR 2.25) and ARMS2 A69S (OR 4.05) polymorphisms as specific genetic predictors.

Living with age-related macular degeneration (AMD) can be frightening because it affects your vision as you get older. Researchers have been looking for ways to better understand why some people develop this condition while others do not. They recently looked at how specific genetic variations, which are small changes in our DNA, play a role in risk.

The study focused on two specific genes: CFH and ARMS2. The results showed that people carrying certain versions of these genes have a higher risk of developing AMD. Specifically, the ARMS2 variation showed a very strong link to the disease. While the data shows a clear connection between these genes and your risk level, it is important to note that some findings were less consistent across different groups.

These findings could eventually help doctors better assess who is at high risk for vision loss. By identifying these genetic markers early, medical teams might one day create more personalized treatment plans. However, because the data shows a lot of variation between different studies, these results are currently used to help understand the disease rather than provide an immediate diagnostic tool.

What this means for you:
Two specific gene variations (CFH and ARMS2) are linked to a higher risk of age-related macular degeneration.

Common questions

What genes are linked to eye disease?

The study identified two specific genetic variations: CFH (Y402H) and ARMS2 (A69S). People who carry the risk versions of these genes show a higher likelihood of developing age-related macular degeneration. The link with the ARMS2 gene was particularly strong in the findings.

How much does my genetics affect my risk?

The data shows that carrying the CFH variant increases risk, while the ARMS2 variation has a very strong association with the disease. Because of differences across various studies, the exact impact can vary, but both genes are clearly linked to higher risk levels.

Can these findings help with treatment?

These genetic markers could eventually help doctors create personalized treatment strategies for patients. While the study notes that some data on specific treatments is not yet clear, identifying these genes helps researchers understand how to better manage risk.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Age-related macular degeneration (AMD) has considerable global burden, being a major cause of vision loss. Subsequently, genetic predisposition holds a role in this case by contributing to disease susceptibility. Polymorphisms in genes such as Complement Factor H (CFH) and Age-Related Maculopathy Susceptibility 2 (ARMS2) play a key role as risk factors for AMD. This systematic review and meta-analysis synthesizes existing evidence to investigate and quantify the association between these polymorphisms and the actual risk of AMD. Additionally, the paper sets to unravel the prevalence of high- and low-risk genotypes among AMD patients. METHODS: In accordance with PRISMA guidelines, we conducted a systematic search of PubMed, Scopus, Web of Science, EMBASE, and the Cochrane Library databases to identify relevant studies. We included primary studies that involved patients diagnosed with AMD and assessed genetic polymorphisms of CFH (Y402H, rs1061170), ARMS2 (A69S, rs10490924), and we included studies evaluating CFH Y402H and ARMS2 A69S in relation to AMD susceptibility and extracted any available data on anti VEGF treatment response for narrative synthesis. The analytical series considered random effects models to perform the associated meta-analyses. Study heterogeneity was assessed using the I² statistic measure as a standard assessment within the studies. The odds ratio (OR) with 95% confidence intervals (CI) was used as the effect measure. RESULTS: The literature search obtained 1,420 studies from which 10 satisfied the eligibility criterion. The meta-analysis utilized eight studies. The association between CFH Y402H polymorphism and AMD risk indicated that the risk of AMD among risk allele carriers was OR 2.25 (95% CI: 1.27-4.00, p = 0.006). ARMS2 polymorphisms demonstrated a strong genetic association to the risk of AMD with an OR of 4.05 (95% CI: 1.79-9.16, p < 0.001). In the second meta-analysis evaluating genotype prevalence, the random-effects model showed an OR of 1.439 (95% CI: 0.929-2.231, p = 0.103), suggesting a variable but moderate prevalence of high-risk genotypes among AMD patients (I² = 95.7%, p < 0.001). CONCLUSIONS: This meta-analysis confirms the significant association between CFH and ARMS2 polymorphisms and AMD susceptibility, emphasizing their role in disease pathogenesis. The findings highlight the potential for genetic screening in AMD risk assessment and personalized treatment strategies. However, substantial heterogeneity across studies underscores the need for standardized methodologies and further research into gene-environment interactions. Integrating genetic risk assessment into clinical practice may improve early detection and targeted interventions for AMD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.